| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.28843 |
| P698 | PubMed publication ID | 27639088 |
| P50 | author | Fabio Marra | Q37841541 |
| P2093 | author name string | Antonio Craxì | |
| Vito Di Marco | |||
| Henry Lik-Yuen Chan | |||
| Grace Lai-Hung Wong | |||
| Jean-Baptiste Hiriart | |||
| Vincent Wai-Sun Wong | |||
| Calogero Cammà | |||
| Victor de Ledinghen | |||
| Salvatore Petta | |||
| Marco Barbara | |||
| Umberto Arena | |||
| Julien Vergniol | |||
| Wassil Merrouche | |||
| Anthony Wing-Hung Chan | |||
| Brigitte Le-Bail | |||
| P2860 | cites work | Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study | Q30418856 |
| EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | Q34676840 | ||
| Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease | Q35893923 | ||
| Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. | Q37257281 | ||
| Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease | Q38080107 | ||
| Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Q38680300 | ||
| Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. | Q41042091 | ||
| Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States | Q41626076 | ||
| Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study | Q42176482 | ||
| Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up | Q42201783 | ||
| Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography | Q42272617 | ||
| Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team | Q42274136 | ||
| Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease | Q44244167 | ||
| Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy | Q47942345 | ||
| "Normal" liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population-based study from a developing country. | Q51005393 | ||
| The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. | Q51089882 | ||
| Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography. | Q51951472 | ||
| MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. | Q52901067 | ||
| Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients | Q57735452 | ||
| Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease | Q58622754 | ||
| The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease | Q58803093 | ||
| Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index | Q58803242 | ||
| Determination of reliability criteria for liver stiffness evaluation by transient elastography | Q59352739 | ||
| The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD | Q61989968 | ||
| Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease | Q82648058 | ||
| Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan® | Q82980218 | ||
| Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease | Q86582636 | ||
| Association between anthropometric parameters and measurements of liver stiffness by transient elastography | Q87396182 | ||
| Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease | Q87406034 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metabolic dysfunction–associated steatotic liver disease | Q1546498 |
| fatty liver disease | Q6058862 | ||
| liver disease | Q929737 | ||
| P304 | page(s) | 1145-1155 | |
| P577 | publication date | 2016-11-05 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values | |
| P478 | volume | 65 |
| Q40238088 | A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B. |
| Q104568218 | Accuracy of Controlled Attenuation Parameter and Liver Stiffness Measurement in Patients with Non-alcoholic Fatty Liver Disease |
| Q92328365 | Berberis aristata, Elaeis guineensis and Coffea canephora Extracts Modulate the Insulin Receptor Expression and Improve Hepatic Steatosis in NAFLD Patients: A Pilot Clinical Trial |
| Q64078374 | Can Nonfibrotic Nonalcoholic Steatohepatitis Be Effectively Identified by Supersonic Shear Imaging? |
| Q42272368 | Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona |
| Q47581786 | Clinical relevance of liver histopathology and different histological classifications of NASH in adults |
| Q54760091 | Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance? |
| Q90223674 | Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis |
| Q41706840 | Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease |
| Q91600205 | Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum |
| Q64065840 | Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis |
| Q48333919 | Do we need controlled attenuation parameter adjustment for fibrosis estimation in nonalcoholic fatty liver disease patients? |
| Q89471889 | Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial |
| Q54250492 | Epidemiological features of chronic hepatitis C infection caused by remunerated blood donors: A nearly 27-year period survey. |
| Q91940712 | Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis |
| Q39210299 | Invasive and non-invasive assessment of portal hypertension. |
| Q89968285 | Limitations of non-invasive tests for assessment of liver fibrosis |
| Q57818077 | Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations |
| Q39170830 | Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). |
| Q92900970 | New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode |
| Q89074070 | Non-alcoholic fatty liver disease and the interface between primary and secondary care |
| Q42695154 | Nonalcoholic fatty liver disease: Evolving paradigms. |
| Q49788920 | Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. |
| Q90656425 | Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis |
| Q92829495 | Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension |
| Q91785586 | Practical Use of Transient Elastography in Screening for Nonalcoholic Steatohepatitis in a Japanese Population |
| Q40195442 | Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. |
| Q58727386 | Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study |
| Q90095549 | Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management |
| Q95442738 | Reply |
| Q54226681 | Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. |
| Q33885985 | Risk Assessment of Hepatocellular Carcinoma in General Population by Liver Stiffness in Combination with Controlled Attenuation Parameter using Transient Elastography: A Cross Sectional Study |
| Q46476704 | Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions |
| Q47547885 | Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection |
| Q38655966 | Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. |
| Q92560945 | Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity |
| Q41185516 | Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease. |
| Q48056257 | Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease |
| Q94093775 | UEG Week 2018 Poster Presentations |
| Q58711515 | Ultrasound Grade of Liver Steatosis Is Independently Associated with the Risk of Metabolic Syndrome |
| Q33584964 | Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study |
| Q90205951 | Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis |
Search more.